NHI Announces Promotion of Kevin Pascoe to Chief Investment Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cantor Fitzgerald Remains Sidelined on National Health Investors (NHI) After Adjusting Estimates
February 21, 2017 6:55 AM ESTCantor Fitzgerald reiterated a Neutral rating and $75.00 price target on National Health Investors (NYSE: NHI) after adjusting estimates. Cantor lowered 2017 normalized FFO estimates to $5.10 (from $5.17) compared with the $5.16 consensus and the $5.06-5.12 guidance. Cantor also initiated a 2018 normalized FFO estimate of $5.30 compared to consensus of... More
